REFLEX:: a phase III trial to assess the effect of dosing frequency of interferon beta-1 a (Rebif®) in delaying conversion of patients with a clinically isolated syndrome to clinically definite multiple sclerosis

被引：0
|
作者：
Kappos, L.
Freedman, M.
De Stefano, N.
Labauge, R.
Comi, G.
Stubinski, B.
机构：
来源：
JOURNAL OF NEUROLOGY | 2007年 / 254卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [21] Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis
    Brettschneider, J
    Petzold, A
    Junker, A
    Tumani, H
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (02) : 143 - 148
  • [22] Cost-utility of interferon beta-1b in the treatment of patients with a clinically isolated syndrome suggestive of multiple sclerosis
    Caloyeras, J. P.
    Wang, C.
    Bauer, L.
    Lee, W. C.
    Lanius, V
    Gondek, K.
    VALUE IN HEALTH, 2008, 11 (03) : A141 - A141
  • [23] The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis
    Motamed, Mohammad Reza
    Najimi, Neda
    Fereshtehnejad, Seyed-Mohammad
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2007, 109 (04) : 344 - 349
  • [24] COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN
    Arbizu, T.
    Pinol, C.
    Casado, V
    VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [25] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial (vol 374, pg 1503, 2009)
    Comi, G.
    Martinelli, V
    Rodegher, M.
    LANCET, 2010, 375 (9724): : 1436 - 1436
  • [26] Magnetic Resonance Imaging Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Two Dosing Frequencies of Subcutaneous Interferon Beta-1a in Patients with Clinically Isolated Syndrome (REFLEX)
    De Stefano, Nicola
    Comi, Giancarlo
    Freedman, Mark S.
    Kappos, Ludwig
    Hennessy, Brian
    Casset-Semanaz, Florence
    Lehr, Lorenz
    Stubinski, Bettina
    NEUROLOGY, 2011, 76 (09) : A359 - A359
  • [27] Relevance of Brain Lesion Distribution and Frequency for Short-Term Conversion of Patients with Clinically Isolated Syndrome to Multiple Sclerosis
    Giorgio, Antonio
    Battaglini, Marco
    Rocca, Maria
    Absinta, Martina
    Barkhof, Frederik
    Rovira, Alex
    Tintore-Subirana, Maria
    Chard, Declan
    Ciccarelli, Olga
    Enzinger, Christian
    Gasperini, Claudio
    Frederiksen, Jette
    Filippi, Massimo
    De Stefano, Nicola
    NEUROLOGY, 2012, 78
  • [28] Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
    Leist, Thomas P.
    Comi, Giancarlo
    Cree, Bruce A. C.
    Coyle, Patricia K.
    Freedman, Mark S.
    Hartung, Hans-Peter
    Vermersch, Patrick
    Casset-Semanaz, Florence
    Scaramozza, Matthew
    LANCET NEUROLOGY, 2014, 13 (03): : 257 - 267
  • [29] Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain
    Pinol, C.
    NEUROLOGIA, 2016, 31 (04): : 247 - 254
  • [30] Rebif® New Formulation (RNF; interferon beta-1 a):: 1-year results of a phase IIIb study in patients with relapsing forms of multiple sclerosis
    Sorensen, P.
    Barbarash, O.
    Casset-Semanaz, F.
    Giovannoni, G.
    King, J.
    Metz, L.
    Pardo, G.
    Simsarian, J.
    Stubinski, B.
    JOURNAL OF NEUROLOGY, 2007, 254 : 15 - 15
12345